Golden M A, Whittemore A D, Donaldson M C, Mannick J A
Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.
Ann Surg. 1990 Oct;212(4):415-20; discussion 420-3. doi: 10.1097/00000658-199010000-00004.
Reduction of cardiac mortality associated with abdominal aortic aneurysm (AAA) repair remains an important goal. Five hundred consecutive urgent or elective operations for infrarenal nonruptured AAA were reviewed. Patients were divided into three groups based on preoperative cardiac status: group I (n = 260, 52%), no clinical or electrocardiographic (ECG) evidence of coronary artery disease (CAD); group II (n = 212, 42.2%), clinical or ECG evidence of CAD considered stable after further evaluation with studies such as dipyridamole-thallium scanning, echocardiography, or coronary arteriography; group III (n = 28, 5.6%), clinical or ECG evidence of CAD considered unstable after further evaluation. Group I had no further cardiac evaluation and groups I and II underwent AAA repair without invasive treatment of CAD. Group III underwent repair of cardiac disease before (n = 21) or coincident with (n = 7) AAA repair. In all instances, perioperative fluid volume management was based on left ventricular performance curves constructed before operation. The 30-day operative mortality rate for AAA repair in all 500 patients was 1.6% (n = 8). There was one (0.4%) cardiac-related operative death in group I, which was significantly less than the five (2.4%) in group II (p less than 0.02). Total mortality for the two groups were also significantly different, with one group I death (0.4%) and seven group II deaths (3.3%), (p less than 0.02). These data support the conclusions that (1) the leading cause of perioperative mortality in AAA repair is myocardial infarction, (2) correction of severe or unstable CAD before or coincident with AAA repair is effective in preventing operative mortality, (3) patients with known CAD should be investigated more thoroughly to identify those likely to develop perioperative myocardial ischemia so that their CAD can be corrected before AAA repair, and (4) patients with no clinical or ECG evidence of CAD rarely die of perioperative myocardial infarction, and thus selective evaluation of CAD based on clinical grounds in AAA patients is justified.
降低与腹主动脉瘤(AAA)修复相关的心脏死亡率仍然是一个重要目标。回顾了500例连续性的肾下非破裂性AAA急诊或择期手术。根据术前心脏状况将患者分为三组:第一组(n = 260,52%),无冠状动脉疾病(CAD)的临床或心电图(ECG)证据;第二组(n = 212,42.2%),经双嘧达莫-铊扫描、超声心动图或冠状动脉造影等进一步评估后,CAD的临床或ECG证据被认为稳定;第三组(n = 28,5.6%),经进一步评估后,CAD的临床或ECG证据被认为不稳定。第一组未进行进一步的心脏评估,第一组和第二组在未对CAD进行侵入性治疗的情况下接受了AAA修复。第三组在AAA修复前(n = 21)或同时(n = 7)进行了心脏病修复。在所有情况下,围手术期液体容量管理基于术前构建的左心室功能曲线。所有500例患者中AAA修复的30天手术死亡率为1.6%(n = 8)。第一组有1例(0.4%)与心脏相关的手术死亡,显著低于第二组的5例(2.4%)(p < 0.02)。两组的总死亡率也有显著差异,第一组1例死亡(0.4%),第二组7例死亡(3.3%),(p < 0.02)。这些数据支持以下结论:(1)AAA修复围手术期死亡的主要原因是心肌梗死;(2)在AAA修复前或同时纠正严重或不稳定的CAD对预防手术死亡有效;(3)已知CAD的患者应进行更彻底的检查,以识别那些可能发生围手术期心肌缺血的患者,以便在AAA修复前纠正其CAD;(4)无CAD临床或ECG证据的患者很少死于围手术期心肌梗死,因此基于临床理由对AAA患者进行CAD的选择性评估是合理的。